The Lustgarten Foundation for Pancreatic Cancer Research Company Profile

11:19 EST 29th January 2015 | BioPortfolio

Founded in 1998 by Cablevision executive Marc Lustgarten, with Cablevision chairman Charles Dolan and CEO James Dolan, The Lustgarten Foundation is the nation's largest private, non-profit supporter of pancreatic cancer research, providing more than $20 million to date. The Foundation provides patient information and manages a national public awareness campaign. To learn more and to see Dr. Pausch's PSA, visit www.lustgarten.org.


News Articles [7033 Associated News Articles listed on BioPortfolio]

3-D culture system for pancreatic cancer has potential to change therapeutic approaches

(Cold Spring Harbor Laboratory) Pancreatic cancer is one of the most deadly forms of cancer, with only 6 percent of patients surviving five years after diagnosis. Today, CSHL and The Lustgarten Founda...

Seven new projects announced by the UK's Pancreatic Cancer Research Fund

(Pancreatic Cancer Research Fund) The UK research charity, the Pancreatic Cancer Research Fund, has invested £1.2 million into seven ambitious new research projects. The announcement coincides with W...

Factors that may contribute to pancreatic cancer: New insight

New research provides a better understanding of pancreatic cancer, and may help identify individuals at increased risk. Pancreatic cancer is a stealthy cancer that is usually detected at very late sta...

Armed virus shows promise as treatment for pancreatic cancer

(Pancreatic Cancer Research Fund) A new combination of two different approaches -- virotherapy and immunotherapy -- is showing 'great promise' as a treatment for pancreatic cancer, according to new re...

Loss of loved ones drives a family's determination to eradicate cancer

(University of Hawaii Cancer Center) A Hawaii family's $50,000 gift funds pancreatic cancer research in Hawaii. The donation is in memory of family members lost to cancer. It will fund a study at the ...

What Makes Pancreatic Cancer so Aggressive?

New research from the University of Michigan Comprehensive Cancer Center helps explain why pancreatic cancer is so lethal, with fewer than a third of patients surviving even early stage disease.  

Pancreatic cancer survival rates at standstill for four decades

Long-term survival from pancreatic cancer has failed to improve in 40 years – with the outlook remaining the lowest of the 21 most common cancers, according to new figures published by Cancer Resear...

Cancer Research UK and Astellas join forces on pancreatic cancer treatment

Japanese drug major Astellas Pharma is joining forces with Cancer Research UK and its commercial arm, Cancer Research Technology (CRT), to find new drug targets in the fight against cancer, with an in...

PubMed Articles [8735 Associated PubMed Articles listed on BioPortfolio]

A Decrease in miR-150 Regulates the Malignancy of Pancreatic Cancer by Targeting c-Myb and MUC4.

Pancreatic cancer is an aggressive cancer with high mortality. Conventional treatments have little impact on its progression. Limited research investigating the role of oncogene miR-150 specifically i...

Role of pancreatic stellate cells in chemoresistance in pancreatic cancer.

Pancreatic cancer is highly chemoresistant. A major contributing factor is the characteristic extensive stromal or fibrotic reaction, which comprises up to 90% of the tumor volume. Over the last decad...

Activation of the Wnt pathway through Wnt2 promotes metastasis in pancreatic cancer.

Wnt signaling pathway plays an important role in physiological and pathological process, including in the occurrence and development of tumor. The purpose of this study is to determine whether Wnt2 an...

Oxidative stress and cytokines in the pathogenesis of pancreatic cancer.

Pancreatic cancer is one of the most aggressive, drug-resistant and lethal types of cancer with poor prognosis. Various factors including reactive oxygen species, cytokines, growth factors, and extrac...

Synergistic cytotoxic activity of treosulfan and gemcitabine in pancreatic cancer cell lines.

Treatment for advanced pancreatic cancer is still very unsatisfactory. Treosulfan is an alkylating agent used for conventional, as well as high-dose chemotherapy regimens, whereby plasma concentration...

Clinical Trials [3735 Associated Clinical Trials listed on BioPortfolio]

Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer

The purpose of this research study is to try to define the highest doses of temsirolimus and gemcitabine that can be used safely in combination to treat advanced pancreatic cancer. Gemcita...

Safety Study to Determine the Appropriate Dose of Antibody Against Tumor Cells to Best Target Patients With Pancreatic Cancer.

This no treatment research study is being done to find a safe and an appropriate dose of antibody (protein) against tumor cells to best target the cancer in people with pancreatic cancer. ...

BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study

The purpose of this study is to test the safety, activity and best doses of FOLFOX-A which consists of the standard chemotherapy drugs fluorouracil, leucovorin, oxaliplatin and abraxane. E...

Local Invasion of Pancreatic Cancer

Pancreatic cancer often spreads through local invasion into local structures, including fat, blood vessels, nerves, and nearby organs (stomach, duodenum, spleen, bile duct). Local microsco...

Capecitabine and Radiation Therapy in Advanced Pancreatic Cancer

Pancreatic cancer has traditionally been treated with chemotherapy and radiation therapy with limited results. Preliminary studies of parts of this program in patients with advanced panc...

Companies [2366 Associated Companies listed on BioPortfolio]

The Lustgarten Foundation for Pancreatic Cancer Research

Founded in 1998 by Cablevision executive Marc Lustgarten, with Cablevision chairman Charles Dolan and CEO James Dolan, The Lustgarten Foundation is the nation's largest private, non-profit support...

The Lustgarten Foundation

The Lustgarten Foundation, based in Bethpage, New York, is America's largest private foundation dedicated solely to funding pancreatic cancer research. Founded in 1998, the Foundation provides critica...

Sky Foundation, Inc.

After being diagnosed with pancreatic cancer in 2007 and responding well to treatment, Kasselman established Sky Foundation to fund research for the Sky Foundation Pancreatic Cancer Research Fund at t...

Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is the only national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure. The organizat...

Pancreatic Cancer Action

About Pancreatic Cancer Action: 5 year survival rates for pancreatic cancer have not changed in over 40 years and it is our mission to change this by way of increased awareness of pancreatic cancer...

More Information about "The Lustgarten Foundation for Pancreatic Cancer Research" on BioPortfolio

We have published hundreds of The Lustgarten Foundation for Pancreatic Cancer Research news stories on BioPortfolio along with dozens of The Lustgarten Foundation for Pancreatic Cancer Research Clinical Trials and PubMed Articles about The Lustgarten Foundation for Pancreatic Cancer Research for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of The Lustgarten Foundation for Pancreatic Cancer Research Companies in our database. You can also find out about relevant The Lustgarten Foundation for Pancreatic Cancer Research Drugs and Medications on this site too.

Search BioPortfolio:
Loading
Advertisement
Advertisement

Corporate Database Quicklinks



Searches Linking to this Company Record